Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
A.V. Petrov(Federal Almazov North-West Medical Research Centre), A.Yu. Zaritskii(Federal Almazov North-West Medical Research Centre), Yu.A. Alekseeva(Federal Almazov North-West Medical Research Centre), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), D.V. Babenetskaya(Federal Almazov North-West Medical Research Centre), O.S. Pokrovskaya(Endocrinology Research Center), М В Нарейко(Endocrinology Research Center), Л Л Гиршова(Federal Almazov North-West Medical Research Centre), E.S. Urnova(Endocrinology Research Center), D.V. Motorin(Federal Almazov North-West Medical Research Centre)
Cited by 1
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59